The bill inserts a new Section 36 into the NIST Act to establish a National Biopharmaceutical Manufacturing Center of Excellence. NIST’s Director must competitively award a single grant or other transaction agreement to a non‑federal eligible entity to create and operate the center, with objectives including demonstration of flexible manufacturing technologies, standardization of chemistry/manufacturing/controls, workforce training, and supply‑chain strengthening.
Why it matters: the measure aims to close the commercialization gap that prevents lab‑scale biotech advances from reaching U.S. commercial production. It funnels federal support toward a centralized hub to accelerate scale‑up, harmonize technical practices useful to regulators, and develop regional workforce pipelines — all intended to reduce foreign supply dependence and preserve U.S. technological leadership in biopharma manufacturing.
At a Glance
What It Does
Amends the National Institute of Standards and Technology Act to create a competitively awarded, non‑federal National Biopharmaceutical Manufacturing Center of Excellence. The Director may fund facility construction, collaborative scale‑up R&D, workforce training, and related programs via grants or other transaction agreements.
Who It Affects
Eligible applicants are public‑private partnerships, institutions of higher education, or consortia (but not federal entities). Direct impacts fall on biopharmaceutical manufacturers (especially those seeking scale‑up), research universities, workforce‑training providers, and federal agencies that regulate or procure biologics.
Why It Matters
The center centralizes federal support for scaling biomanufacturing and creating common technical practices — potentially lowering barriers to commercialization and easing regulatory review, while concentrating federal investment and influence in one institution.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates a new, standalone Center of Excellence inside the statutory framework of NIST. NIST’s Director must run a competitive solicitation and award a single grant or other transaction agreement to a non‑federal entity that demonstrates experience in biopharma manufacturing, workforce training, and partnership building.
The chosen operator will run demonstrations of flexible, scalable manufacturing platforms, advance upstream and downstream process improvements, and pilot approaches that reduce supply‑chain bottlenecks.
Funding can support capital (construction or facility expansion), collaborative R&D to scale manufacturing approaches to commercial levels, and workforce development programs tied to education and community partners. The Director’s selection criteria favor applicants that can show prior relevant work, regional leverage with existing clusters or training facilities, committed co‑investment, and a plan to deploy impact within a defined timeframe.The bill requires three reporting milestones: an initial report to Congress within one year after award describing establishment progress; a progress report one year after the Center begins operations; and a final report five years after operations begin.
It also requires the Center to establish intellectual property guidelines before operations commence, developed in consultation with similar institutions such as Manufacturing USA institutes.Operationally the statute limits applicants to public‑private partnerships, institutions of higher education, or consortia thereof (explicitly excluding federal entities), and authorizes use of grants or other transaction agreements — a flexible contracting tool. The statute defines key terms (biomanufacturing, biopharmaceutical, biotechnology) and authorizes $120 million for fiscal year 2026 to implement the program.
The Five Things You Need to Know
The Director must solicit applications and make the award within 180 days of enactment, and the statute contemplates a single award to operate the Center of Excellence.
The Center must be a non‑federal entity: eligible applicants are public‑private partnerships, institutions of higher education, or consortia of those entities; federal agencies are ineligible.
The statute authorizes $120,000,000 for fiscal year 2026 to fund construction, collaborative scale‑up R&D, workforce training, and related programs for the Center.
The bill requires IP guidelines to be established before the Center begins operations and directs the Director to consult Manufacturing USA and similar institutions when creating those rules.
Congress receives three statutory reports: an initial report within one year of award, a progress report one year after operations begin, and a final report five years after operations begin.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the measure the "Biomanufacturing Excellence Act of 2025." This is purely cosmetic but signals the bill’s focused aim: catalyzing domestic biopharmaceutical manufacturing capability.
Findings and sense of Congress
Sets out congressional findings about biotechnology’s strategic importance, the commercialization bottleneck for U.S. manufacturers, and the need for flexible, affordable infrastructure and workforce training. While non‑binding, these findings frame congressional intent and will guide how NIST and appropriators interpret the statute’s priorities.
Establishes the Center and lists objectives
Directs the Director of NIST to award a grant or enter into an other transaction agreement with an eligible non‑federal entity to establish the National Biopharmaceutical Manufacturing Center of Excellence. The statute enumerates objectives: demonstrate flexible manufacturing technologies, improve upstream/downstream processes across modalities, standardize chemistry/manufacturing/controls, reduce supply‑chain bottlenecks, and build workforce training partnerships. The breadth of objectives gives the Center latitude to span R&D, infrastructure, and workforce programs.
Competitive award process, eligibility limits, and selection factors
The Director must solicit applications and select one applicant within 180 days. Eligible applicants are limited to public‑private partnerships, institutions of higher education, or consortia (no federal entities). Applications must document prior demonstrations, plans to advance manufacturing for national‑priority products, workforce training experience, partnership networks, and intended use of funds for facilities. Selection criteria emphasize potential impact, workforce development reach, co‑investment, proximity to existing clusters, and time‑to‑operation — giving weight to applicants that can mobilize existing regional assets quickly.
Three statutory reporting milestones and public posting
Requires an initial report to Congress within one year after award covering establishment progress (construction, partnerships), a progress report one year after operations start summarizing activities and findings, and a final report five years after operations start. All reports must be published in a public, searchable electronic format. These cadence requirements create discrete oversight checkpoints for Congress and stakeholders.
IP guidelines, authorization, and definitions
Directs the Director to ensure the Center establishes IP guidelines before operations commence, in consultation with existing institutes like Manufacturing USA, and authorizes $120 million for FY2026. The bill also supplies statutory definitions for biomanufacturing, biopharmaceutical, biotechnology, Executive agency, and institution of higher education — narrowing ambiguity about eligible activities and partners.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Small and medium biopharmaceutical firms seeking scale‑up: the Center provides access to demonstration facilities, shared infrastructure, and technical de‑risking that lower the capital hurdle for moving from pilot to commercial production.
- Universities and community colleges that partner on workforce programs: the statute prioritizes training partnerships and will channel funds and employer connections to credential and placement programs.
- Federal regulators and procurement agencies (e.g., FDA, DOD, HHS): standardized chemistry/manufacturing/control practices and publicly documented demonstrations can shorten regulatory review and improve domestic sourcing for critical biologics.
Who Bears the Cost
- NIST / Federal appropriators: while the bill authorizes $120 million for FY2026, executing the program and sustaining it beyond that authorization will require appropriation decisions and potential reallocation within NIST’s budget.
- Selected Center operator and partners: the award process favors co‑investment, so states, industry partners, or universities will likely need to commit matching funds or in‑kind contributions for facilities and operations.
- Participating firms with proprietary technology: the requirement to establish IP guidelines and the participation model for a shared center may force companies to balance openness needed for standardization against protecting proprietary process IP, complicating commercialization strategies.
Key Issues
The Core Tension
The central trade‑off is between using a concentrated federal investment to rapidly de‑risk and standardize biomanufacturing (speed and coordination) versus preserving competitive market incentives and geographic plurality (competition and private IP protections); accelerating commercialization often requires openness and shared infrastructure, but doing so can dilute firms’ proprietary advantages and concentrate federal influence in one selected institution.
Two implementation tensions stand out. First, the bill concentrates federal backing in a single competitively selected non‑federal center.
That design can accelerate impact by creating a focal node, but it risks geographic concentration and the political optics of "picking winners." The statutory selection factors try to mitigate this by valuing regional leverage and co‑investment, yet the choice of one operator leaves other viable regional ecosystems without the same federal anchor.
Second, the statute pushes for standardization and public sharing of best practices while requiring IP guidelines before operations start. That combination is sensible in principle but hard in practice: companies want to protect process know‑how that creates commercial advantage while regulators and public funders want reproducible, open methods.
The bill provides no detail on licensing approaches, revenue sharing, or how background and foreground IP will be handled in collaborative projects. Finally, the authorization is a single‑year dollar figure ($120M for FY2026) with no guaranteed follow‑on funding; establishing facilities, training pipelines, and durable industry partnerships generally requires multi‑year funding certainty that the statute does not itself deliver.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.